Cardiff Oncology Publishes Data From Phase 2 Trial In Second-Line KRAS Mutant mCRC
CARDIFF ONCOLOGY INC CRDF | 3.92 3.80 | -3.69% -3.06% Pre |
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -
- Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients -
- Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC -
- Initial readout from first-line RAS-mutant mCRC CRDF-004 trial expected in H2 2024 -
